Differentiating Infected from Vaccinated Individuals via Marker-Based Assays

You are reading version 1 of this direction, frozen 2026-10-04. The latest version is version 2.

Version 1 of 211 papers17 conceptsfrozen 2026-10-04

In the effort to control infectious diseases, vaccination is our most powerful tool. However, it creates a paradox for public health surveillance: once a population is widely vaccinated, traditional antibody tests can no longer distinguish between an individual who is immune because of a vaccine and one who is currently carrying a wild-type pathogen.

This "diagnostic interference" makes it nearly impossible to track the actual spread of a virus or to identify and isolate infected individuals within a vaccinated group. To solve this, researchers have developed the DIVA (Differentiating Infected from Vaccinated Animals/Individuals) strategy. By pairing "marker vaccines" with specific diagnostic assays, we can maintain a clear window into the movement of a disease even during mass immunization campaigns.

The Mechanism of Negative Markers

The core intuition behind DIVA is the "negative marker" strategy. If a vaccine is designed to include every part of a pathogen, the immune system produces a broad spectrum of antibodies that look identical to those triggered by a natural infection.

To create a DIVA-compatible system, researchers like Zhi-qiang Li and Hui Zhang engineer vaccines that are "missing" a specific, non-essential immunogenic protein. For example, in their work on Brucella abortus, they deleted the wbkA gene to create a mutant strain (Immunization of BALB/c mice with Brucella abortus 2308ΔwbkA confers protection against wild-type infection).

When an animal is vaccinated with this strain, it develops immunity to the bacteria but never produces antibodies against the WbkA protein. If a diagnostic test later detects WbkA antibodies, the veterinarian knows with certainty that the animal has been exposed to the wild-type "field" strain, not just the vaccine. Similar strategies have been applied to Brucella melitensis by deleting the TcfSR regulatory system (Brucella melitensis 16MΔTcfSR as a potential live vaccine allows for the differentiation between natural and vaccinated infection).

Dual-Target Assays for High-Throughput Screening

In the swine industry, where diseases like Pseudorabies Virus (PRV) cause massive economic losses, the DIVA strategy is essential for eradication. chihai ji and Jingyu Wang developed dual-fluorescent microsphere assays that simultaneously target two different viral proteins: gB and gE (Development of Dual Fluorescent Microsphere Immunological Assay for Detection of Pseudorabies Virus gE and gB IgG Antibodies).

In this system:

  1. gB (Conserved): Present in both the vaccine and the wild virus. A positive result indicates the animal has some form of immunity.
  2. gE (Deleted): Present only in the wild virus. A positive result here flags a natural infection.

This allows for high-throughput screening where a single blood sample provides a complete immune profile, identifying "silent" carriers in a vaccinated herd. This is particularly vital because, as Lu Tu and Shaohua Hou have shown, even attenuated vaccine strains can sometimes circulate in unintended populations, such as cats, making precise molecular differentiation a necessity for safety monitoring (Assessing the Risk of Commercial Vaccines Against Pseudorabies Virus in Cats).

DIVA in Human Public Health: The SARS-CoV-2 Case

While DIVA is a long-standing pillar of veterinary medicine, the COVID-19 pandemic brought these concepts into human public health. Most major SARS-CoV-2 vaccines target only the Spike (S) protein. Natural infection, however, exposes the immune system to the entire virus, including the Nucleocapsid (N) protein.

Researchers like Simon Merkt and Solomon Ali used this accidental DIVA property to estimate the true infection rate in Ethiopia, finding that cases were under-reported by a factor of ten (Long-term monitoring of SARS-CoV-2 seroprevalence and variants in Ethiopia provides prediction for immunity and cross-immunity). By tracking N-antibodies (infection markers) alongside S-antibodies (vaccine/infection markers), they could map the rise of "hybrid immunity."

However, this natural DIVA system has limitations. Jelena Bešević and Ben Lacey found that while Spike antibodies remain robust for over 18 months, Nucleocapsid antibodies fade significantly faster (Persistence of SARS-CoV-2 antibodies over 18 months following infection: UK Biobank COVID-19 Serology Study). This suggests that for long-term surveillance, we cannot rely on accidental markers; we must intentionally design vaccines and assays with high-persistence markers in mind.

The Path to Eradication

The ultimate goal of the DIVA strategy is the transition from disease control to total eradication. As Da Shi and Li Feng argue, the ability to identify and remove naturally infected individuals from a population—without stopping vaccination—is the only way to clear a pathogen from a region (The technologies and their applications in the prevention and control of main porcine viral diarrhea).

Whether through the development of new ELISAs for African Swine Fever (A highly efficient indirect ELISA and monoclonal antibody established against African swine fever virus pK205R) or longitudinal cohort studies like Munich's KoCo19 led by Katja Radon (The representative COVID-19 cohort Munich (KoCo19): from the beginning of the pandemic to the Delta virus variant), the integration of molecular markers into our immunization strategy ensures that we are never "blinded" by our own vaccines.

Papers in this version

History & citationVersion 2 · 2026-10-04

Current · Permanent link

  1. Version 2 (latest) · 2026-10-04 · 15 papers
  2. Version 1 · 2026-10-04 · 11 papers
Cite this direction

Latest version (a living page):

@misc{lacuna_diva_strategy_c2b75f06,
  title = {DIVA strategy},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/diva-strategy/rdr_c2b75f06d7004616a2e89e11c4377972},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-20},
}

This exact version (version 1, frozen text):

@misc{lacuna_differentiating_infected_from_vaccinated_c2b75f06_v1,
  title = {Differentiating Infected from Vaccinated Individuals via Marker-Based Assays},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/differentiating-infected-from-vaccinated-individuals-via-marker-based-assays/rdr_c2b75f06d7004616a2e89e11c4377972/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-20},
}